Cargando…

Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells

Pancreatic cancer stem cells (CSCs) play a crucial role in tumorigenesis and chemoresistance of pancreatic ductal adenocarcinoma. Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel secretory protein, has been shown to contribute to cancer progression and metastasis. Because the clinical r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Jae Hee, Kim, Sun A., Park, Soo Been, Kim, Hee Man, Song, Si Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652714/ https://www.ncbi.nlm.nih.gov/pubmed/29100320 http://dx.doi.org/10.18632/oncotarget.19458

Ejemplares similares

Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer
por: Choi, Chel Hun, et al.
Publicado: (2018)

Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer
por: Song, Jinhoi, et al.
Publicado: (2016)

PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer
por: Kim, Yeon Jeong, et al.
Publicado: (2022)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor
por: Yoo, Wonbeak, et al.
Publicado: (2021)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF-κB Signaling Pathway
por: Youn, So Eun, et al.
Publicado: (2022)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017)

Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
por: Öman, Mikael, et al.
Publicado: (2021)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2021)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer
por: Murase, Hiromichi, et al.
Publicado: (2023)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Barriers and opportunities for gemcitabine in pancreatic cancer therapy
por: Beutel, Alica K., et al.
Publicado: (2023)

Determinants of gemcitabine response in pancreatic cancer: are we there?
por: Fitzpatrick, Orla M., et al.
Publicado: (2023)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
por: Liu, Kaidong, et al.
Publicado: (2022)

Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells
por: Xing, Hai-Bo, et al.
Publicado: (2018)

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner
por: Spek, C. Arnold, et al.
Publicado: (2022)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm
por: Lee, Jaehoon, et al.
Publicado: (2021)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Chen, Ru, et al.
Publicado: (2017)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
por: Damaraju, Vijaya L, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_uf4fk2s2d7h9fsjqc9bqh69rhp